Beyond Air, Inc. Form 8-K Summary
Business Context and Reporting Period
Beyond Air, Inc. (XAIR), a Delaware corporation, filed this Current Report on Form 8-K on June 15, 2023. The filing discloses the entry into a material definitive agreement involving a new senior secured term loan facility and the issuance of warrants to the lenders.
Key Financial Metrics and Transaction Details
The Company entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. and related funds. Key terms include:
- Total Facility Size: Up to $40 million in aggregate principal.
- Initial Funding (Tranche 1): $17.5 million advanced on the Closing Date (June 15, 2023).
- Future Tranches: Up to $10 million (Tranche 2) contingent on revenue milestones between April 1, 2024, and September 30, 2024; and up to $12.5 million (Discretionary Tranche) subject to lender approval after April 1, 2024.
- Maturity Date: June 1, 2027.
- Interest Rate: The greater of (i) Prime Rate + 3.75% or (ii) 12.00% per annum.
- Repayment: Equal monthly installments beginning January 1, 2025, with potential deferral options based on revenue performance.
- Prepayment Fees: Ranging from 3.00% (within 1 year) to 1.00% (after 3 years), plus a 3.50% final payment fee on Tranche 1 and 2.
- Warrants Issued: Warrants to purchase approximately 233,843 shares of common stock were issued to the lenders. The exercise price is the lesser of $5.88 or the price of the next bona fide equity financing before June 30, 2024.
- Liquidity Covenant: The Company must maintain at least $5,000,000 in unrestricted cash at all times.
Material Changes and Covenants
This filing represents a significant change in the Company's capital structure, introducing new debt obligations and potential equity dilution. The Loan Agreement includes standard affirmative and negative covenants that restrict the Company's ability to incur additional debt, pay dividends, engage in change of control transactions, or dispose of assets without lender consent. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the current period versus prior periods, as this is a transactional filing rather than a periodic financial report.
Outlook, Risks, and Contingencies
Management intends to use the loan proceeds for general corporate purposes. The transaction includes specific risks and contingencies:
- Revenue Milestones: Access to the $10 million Tranche 2 is contingent on achieving 85% of projected Product Revenue (specifically from LungFit PH sales) in the three months prior to funding.
- Conversion Rights: Lenders have the right to convert up to $3 million of outstanding principal into common stock at 130% of the warrant exercise price.
- Participation Rights: Lenders may participate in future equity financings up to $1,000,000 on the same terms as other investors for 18 months.
- Collateral: The loans are secured by a pledge of substantially all assets of the Company and its subsidiaries.
Key Facts for Investor Verification
- Verify the Company's current unrestricted cash balance to ensure compliance with the $5 million minimum covenant.
- Monitor the Company's LungFit PH product revenue to assess the likelihood of drawing the $10 million Tranche 2.
- Review the impact of the 12.00% minimum interest rate and prepayment fees on future cash flow projections.
- Assess the potential dilution from the 233,843 warrants issued and the $3 million conversion right.
- Confirm the status of the registration statement for the resale of shares issuable upon warrant exercise, which must be filed within 60 days of the closing date.